Exagen opened lower at $5.02, compared with its previous close of $5.04. In the last trading session, the stock traded between $4.39 and $5.10. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Exagen is now worth
$ 31.47
Resulting in a loss of
$ 68.53 (68.53%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.62 (-12.37%)
Day High
$5.10
Day Low
$4.39
Day Open
$5.02
Prev Close
$5.04
Volume
12,20,131
1W Return
-48.32%
1M Return
-46.54%
3M Return
-34.83%
6M Return
10.85%
1Y Return
-52.15%
Fundamentals
Market Cap ($ Mn)
113
PE Ratio
-
PB Ratio
14.62
PEG Ratio
-
ROE
-137.47%
ROCE
-39.73%
EPS (TTM)
$-0.25
Investment Returns
1 Week
-48.32%
1 Month
-46.54%
3 Months
-34.83%
6 Months
10.85%
9 Months
33.70%
Financials
Quarterly
All values in $ Mn
17.2
Sep 25
16.6
Dec 25
0.0
Mar 26
17.3
Mar 26
19.9
Jun 26
18.4
Sep 26
Updates
10Nov
Exagen files prospectus for $150M mixed shelf offering
Exagen Inc filed a prospectus for a mixed shelf offering worth up to $150 million. The filing was submitted to the U.S. Securities and Exchange Commission (SEC). The offering covers various securities including common stock, debt, and warrants. Specific terms and pricing will be determined at the time of future sales.
Exagen reported Q3 revenue of $18.417 million, beating consensus estimates by 0.40%. Loss per share widened to $(0.25), missing analyst expectations of $(0.18). Trailing 12-month ASP hit a record $451, marking 14 consecutive quarters of improvement. Adjusted EBITDA improved more than 30% year-to-date as revenue outpaced expense growth. FY26 revenue guidance reaffirmed at $72 million-$75 million, below current consensus.
2 days ago
19Oct
Canaccord Genuity raises Exagen price target to $11, maintains Buy
Canaccord Genuity raised Exagen's price target to $11 from $9. The firm maintains a Buy rating on the stock. Analyst Kyle Mikson issued the updated rating and target.
Revenue reached a record $19.9 million, up 16% YoY, driven by volume and ASP growth. Adjusted EBITDA loss narrowed to $0.1 million from $1.7 million a year ago, nearing breakeven. Trailing 12-month ASP rose to $446, marking the 13th consecutive quarter of price growth. Pharma Services revenue exceeded $1 million for the first time, up over 200% YoY. Full-year revenue guidance raised to $72-75 million, citing strong H1 execution.
1mo ago
25Jun
Roth Capital initiates Exagen coverage with Buy rating, $8 target
Roth Capital analyst Max Masucci has initiated coverage on Exagen with a Buy rating and a price target of $8, signaling a positive outlook for the stock.
